Our commitment to innovative drug development
We focus on developing therapies that target the root causes of aging-related diseases, with a specialized focus on HGPS, aiming to improve health span and quality of life.
Our dedication to innovative drug development aims to address age-related diseases.
Focusing on therapies for Hutchinson-Gilford Progeria Syndrome (HGPS), we pioneer solutions that target the root causes of accelerated aging in children. Our scientific approach combines cutting-edge research with compassionate care to improve health outcomes for this rare disease.
Our Experts
Aarav Sharma
Chief Scientific Officer
Our Chief Scientific Officer has over 20 years of experience in aging research and novel therapy development, leading innovative projects in the field.
Mateo García
Lead Research Scientist
The Lead Research Scientist specializes in studying rare pediatric diseases like HGPS and has published extensively on cellular aging mechanisms.
Zuri Ndlovu
Clinical Development Director
Our Clinical Development Director has a decade of experience in advancing therapies from bench to bedside, with a focus on age-related diseases.
Leila Haddad
Bioinformatics Specialist
The Bioinformatics Specialist uses advanced computational techniques to identify potential drug targets related to aging and HGPS.
Eolas Longevity 